Insider Selling: Alphatec (NASDAQ:ATEC) Director Sells 250,000 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Pelizzon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the sale, the director directly owned 10,395,045 shares of the company’s stock, valued at approximately $204,366,584.70. This trade represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alphatec Trading Up 1.5%

ATEC stock traded up $0.30 during mid-day trading on Thursday, reaching $19.87. 1,203,104 shares of the stock traded hands, compared to its average volume of 2,040,826. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The stock has a market capitalization of $2.95 billion, a PE ratio of -19.11 and a beta of 1.08. The business has a 50-day moving average price of $18.90 and a two-hundred day moving average price of $15.29. Alphatec Holdings, Inc. has a one year low of $8.70 and a one year high of $22.66.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analysts’ expectations of $182.78 million. The firm’s quarterly revenue was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.28) EPS. Equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Emerald Advisers LLC lifted its stake in shares of Alphatec by 3.8% in the second quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company’s stock worth $18,696,000 after buying an additional 60,885 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Alphatec by 7.6% during the 1st quarter. AQR Capital Management LLC now owns 676,897 shares of the medical technology company’s stock worth $6,864,000 after buying an additional 47,939 shares during the period. American Century Companies Inc. boosted its stake in Alphatec by 6.0% in the 2nd quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company’s stock valued at $68,567,000 after buying an additional 347,130 shares in the last quarter. Northern Trust Corp grew its position in Alphatec by 3.4% in the first quarter. Northern Trust Corp now owns 1,049,469 shares of the medical technology company’s stock valued at $10,642,000 after acquiring an additional 34,726 shares during the period. Finally, Voya Investment Management LLC raised its stake in Alphatec by 60.1% during the first quarter. Voya Investment Management LLC now owns 49,561 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 18,605 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ATEC shares. Loop Capital set a $25.00 price target on shares of Alphatec in a report on Wednesday, December 10th. Canaccord Genuity Group increased their price target on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Morgan Stanley set a $23.00 price objective on Alphatec in a research report on Tuesday, December 2nd. JPMorgan Chase & Co. initiated coverage on Alphatec in a report on Friday, October 24th. They issued an “overweight” rating and a $19.00 price objective on the stock. Finally, Wall Street Zen cut Alphatec from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.